Guideline Recommendations for GERD Management with Proton‑Pump Inhibitors

Primary Treatment Strategy

• PPI monotherapy is the cornerstone of gastro‑oesophageal reflux disease (GERD) management; routine combination with antacids is not recommended. [@1]

Initial Dosing and Escalation

• Begin with a once‑daily PPI taken 30–60 minutes before breakfast for a trial of 4–8 weeks. [@3]
• If symptoms remain inadequate after the initial trial, increase to twice‑daily PPI (before breakfast and dinner) for an additional 4 weeks. [@1]
• A therapeutic response is considered positive when symptom frequency is reduced by ≥75 %. [@1]

Efficacy of Twice‑Daily PPI Therapy

• Twice‑daily PPI dosing is more sensitive than pH monitoring for confirming GERD, supporting its use as an initial diagnostic‑therapeutic approach. [@2]
• Persistent abnormal acid exposure occurs in <4 % of patients on twice‑daily PPIs versus ~30 % on once‑daily dosing. [@4]

Role of Antacids

• Antacids may be used as rescue therapy for breakthrough symptoms while awaiting full PPI effect; they should not replace or be combined as primary therapy. [@5]
• Reliance on antacids for self‑treatment can delay appropriate evaluation and mask serious conditions. [@5]

Monitoring and Management of Refractory Cases

• After failure of twice‑daily PPI, do not further increase the PPI dose or add antacids as primary therapy; instead, proceed to pH/impedance monitoring while continuing the twice‑daily regimen. [@2]
• Monitoring helps identify the underlying mechanism: ~7 % have inadequate acid suppression, ~60 % have non‑acid reflux, and the remainder may have a hypersensitive esophagus. [@1]
• Approximately 60 % of PPI‑refractory patients show a positive symptom association with non‑acid reflux, which does not respond to additional acid suppression or antacids. [@2]

Timing and Administration of PPIs

• PPIs must be taken 30–60 minutes before meals (not with meals or at bedtime) to achieve optimal activation in the acidic parietal‑cell canaliculi. [@3]
• For twice‑daily regimens, split the doses to be taken before breakfast and before dinner. [@3]

Common Pitfalls to Avoid

• Do not use antacids as monotherapy or as a co‑primary therapy for GERD; they are adjuncts only for breakthrough symptoms. [@5]
• Do not start treatment with twice‑daily PPI for uncomplicated non‑erosive GERD; this is inappropriate first‑line therapy. [@2]
• Do not continue escalating PPI doses beyond twice‑daily without objective testing (pH/impedance monitoring) to determine the cause of treatment failure. [@1]